Scripps Research Names Jin-Quan Yu to Newly-Endowed Bristol Myers Squibb Chair in Chemistry
Bristol Myers Squibb (NYSE: BMY) has endowed a $3 million chair in chemistry at Scripps Research to boost drug discovery research. Professor Jin-Quan Yu, a prominent chemist, will be the inaugural holder. This partnership aims to facilitate the translation of academic research into biopharma, enhancing the development of new medicines. The collaboration highlights ongoing efforts to tackle global health challenges through innovative chemistry, with Yu's previous work paving the way for significant advancements in pharmaceutical chemistry.
- Endowed $3 million chair supports drug discovery initiatives.
- Collaboration strengthens ties between academia and biopharma.
- Jin-Quan Yu's expertise brings transformative potential for new medicines.
- None.
PRINCETON, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Scripps Research today announced that Bristol Myers Squibb has endowed a chair in chemistry at Scripps Research to advance scientific research critical to drug discovery.
Scripps Research has named Professor Jin-Quan Yu, PhD, a pioneering chemist whose research has paved the way to powerful new techniques used in fields ranging from drug discovery to materials science, to be the inaugural holder of the Bristol Myers Squibb Endowed Chair in Chemistry.
“Bristol Myers Squibb and Scripps Research have had a long-standing relationship and we are proud to endow this chair to support transformative research with unrestricted funding,” said Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil., Executive Vice President and President, Research & Early Development, Bristol Myers Squibb. “We look forward to further groundbreaking chemistry to emerge from Scripps Research.”
“Academic research serves as a wellspring for advancements in medicine,” said Peter Schultz, PhD, president and CEO of Scripps Research. “Looking at how a drug can progress from a discovery in our labs to an approved medicine for patients, it becomes clear that effective translation of academic discoveries to biopharma is essential for tackling the world’s health challenges.”
Schultz continued, “The new
Yu received his doctorate in chemistry from the University of Cambridge in 1999. He subsequently held positions as a postdoctoral fellow at Harvard University and as a junior faculty member at Cambridge and Brandeis University. He joined the faculty at Scripps Research in 2007, where he is the Frank and Bertha Hupp Professor of Chemistry.
In 2016, he was named a MacArthur Fellow for pioneering new methods in chemistry and enabling the development of versatile, novel and beneficial chemical compounds. His work was cited by the MacArthur Foundation as “breaking down barriers to the development of versatile compounds with enormous benefits to academic, industrial, and pharmaceutical research.”
Yu’s research team has published more than 200 papers in influential research journals and has forged collaborations with academic and industry leaders around the world. This includes a collaboration with Bristol Myers Squibb researchers to develop a valuable new technique, known as “ligand-accelerated non-directed C–H functionalization,” that has already found application in pharmaceutical chemistry and a wide range of other chemical industries.
“I’m honored that Scripps Research has named me to be the Bristol Myers Squibb Endowed Chair in Chemistry,” says Yu. “This support ensures my team has the flexibility and resources to continue to pursue the most interesting and high-impact ideas.”
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.
Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.
About Scripps Research
Scripps Research is ranked the most influential institution in the world for its impact on innovation. We expand basic knowledge in the biosciences, and use these fundamental advancements to develop profound innovations that improve wellbeing. Our researchers lead breakthrough studies that address the world’s most pressing health concerns. Our educational and training programs mold talented and committed students and postdocs into the next generation of leading scientists. We are accelerating the creation and delivery of medical breakthroughs to better human health around the globe.
corporatefinancial-news
